Keefe Dorothy M
Discipline of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Curr Opin Oncol. 2007 Jul;19(4):323-7. doi: 10.1097/CCO.0b013e3281214412.
To describe the advances in the rapidly evolving field of intestinal (or alimentary) mucositis during the past year.
Major advances have been made in both the clinical and preclinical setting, with the publication of a suite of articles regarding the pathobiology and management of mucositis, as well as several articles on important basic research in the area. The mechanism of mucositis development is now understood to be much more complex than previously thought, with an interplay of host and drug factors leading to overt damage, and variation in manifestation of that damage depending on the specific region of the gut. The MASCC/ISOO management guidelines for mucositis have been updated: a recommendation for the use of palifermin in the hematology transplant setting has been added, and a couple of previous recommendations have been revoked. This marks an important milestone in mucositis, as it is the first time a drug has been available that substantially reduces the occurrence and severity of mucositis.
There is still much to be done to abolish the severe toxicity of chemotherapy and radiotherapy; however, progress is accelerating, and new targeted drugs are becoming available.
描述过去一年中快速发展的肠道（或消化道）黏膜炎领域的进展。
临床和临床前研究均取得了重大进展，发表了一系列关于黏膜炎病理生物学和管理的文章，以及该领域一些重要基础研究的文章。目前认为，黏膜炎发生的机制比以前认为的要复杂得多，宿主和药物因素相互作用导致明显损伤，且损伤表现因肠道特定区域而异。MASCC/ISOO黏膜炎管理指南已更新：增加了在血液学移植环境中使用帕利夫明的建议，撤销了一些先前的建议。这标志着黏膜炎领域的一个重要里程碑，因为这是首次有药物能够大幅降低黏膜炎的发生率和严重程度。
要消除化疗和放疗的严重毒性仍有许多工作要做；然而，进展正在加速，新的靶向药物不断涌现。
